"Most relapsed/refractory large B cell lymphoma (r/rLBCL) patients receiving anti-CD19 chimeric antigen receptor (CAR19) T cells relapse. To characterize determinants of resistance, we profiled over 700 longitudinal specimens from two independent cohorts"

#CART #immunotherapy #immunology #Lymphoma #LBCL #CD19

https://www.cell.com/cancer-cell/fulltext/S1535-6108(22)00591-8?dgcid=raven_jbs_aip_email